

# 15,472 Dead 1.5 Million Injured (50% Serious) Reported in European Union's Database of Adverse Drug Reactions for COVID-19 Shots

By [Brian Shilhavy](#)

Global Research, June 22, 2021

[Health Impact News](#) 21 June 2021

Region: [Europe](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at [@crg\\_globalresearch](#).

\*\*\*

*The European database of suspected drug reaction reports is [EudraVigilance](#), which also tracks reports of injuries and deaths following the experimental COVID-19 "vaccines."*

A subscriber from Europe recently emailed us and reminded us that this database maintained at EudraVigilance is only for countries in Europe who are part of the European Union (EU), which comprises 27 countries.

The total number of countries in Europe is much higher, almost twice as many, numbering around 50, although there are some differences of opinion as to which countries are technically part of Europe.

So as high as these numbers are, they do NOT reflect all of Europe. The actual number in Europe who are reported dead or injured due to COVID-19 shots would be much higher than what we are reporting here.

The EudraVigilance database reports that through June 19, 2021 there are **15,472 deaths and 1,509,266 injuries** reported following injections of four experimental COVID-19 shots:

- [COVID-19 MRNA VACCINE MODERNA \(CX-024414\)](#)
- [COVID-19 MRNA VACCINE PFIZER-BIONTECH](#)
- [COVID-19 VACCINE ASTRAZENECA \(CHADOX1 NCOV-19\)](#)
- [COVID-19 VACCINE JANSSEN \(AD26.COV2.S\)](#)

From the total of injuries recorded, half of them (753,657) are **serious** injuries.

*"**Seriousness** provides information on the suspected undesirable effect; it can be classified as 'serious' if it corresponds to a medical occurrence that results in **death**, is life-threatening, requires inpatient hospitalisation, results in another medically important condition, or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect."*

A *Health Impact News* subscriber in Europe ran the reports for each of the four COVID-19 shots we are including here. This subscriber has volunteered to do this, and it is a lot of work to tabulate each reaction with injuries and fatalities, since there is no place on the [EudraVigilance](#) system we have found that tabulates all the results.

Since we have started publishing this, others from Europe have also calculated the numbers and confirmed the totals.[1]

Here is the summary data through June 19, 2021.

**Total reactions** for the experimental mRNA vaccine **Tozinameran** (code **BNT162b2,Comirnaty**) from **BioNTech/ Pfizer: 7,420 deaths** and **560,256** injuries to 19/06/2021

- 16,133 Blood and lymphatic system disorders **incl. 81 deaths**
- 12,637 Cardiac disorders **incl. 964 deaths**
- 101 Congenital, familial and genetic disorders **incl. 6 deaths**
- 7000 Ear and labyrinth disorders **incl. 4 deaths**
- 265 Endocrine disorders **incl. 1 death**
- 8,122 Eye disorders **incl. 17 deaths**
- 51,030 Gastrointestinal disorders **incl. 348 deaths**
- 155,486 General disorders and administration site conditions **incl. 2,290 deaths**
- 468 Hepatobiliary disorders **incl. 31 deaths**
- 6,110 Immune system disorders **incl. 32 deaths**
- 17,549 Infections and infestations **incl. 762 deaths**
- 6,275 Injury, poisoning and procedural complications **incl. 104 deaths**
- 13,249 Investigations **incl. 285 deaths**
- 4,162 Metabolism and nutrition disorders **incl. 139 deaths**
- 79,125 Musculoskeletal and connective tissue disorders **incl. 88 deaths**
- 325 Neoplasms benign, malignant and unspecified (incl. cysts and polyps) **incl. 23 deaths**
- 100,895 Nervous system disorders **incl. 780 deaths**
- 384 Pregnancy, puerperium and perinatal conditions **incl. 10 deaths**
- 107 Product issues
- 9,928 Psychiatric disorders **incl. 105 deaths**
- 1,765 Renal and urinary disorders **incl. 115 deaths**
- 2,696 Reproductive system and breast disorders **incl. 3 deaths**
- 23,689 Respiratory, thoracic and mediastinal disorders **incl. 848 deaths**
- 26,641 Skin and subcutaneous tissue disorders **incl. 66 deaths**
- 846 Social circumstances **incl. 10 deaths**
- 281 Surgical and medical procedures **incl. 19 deaths**
- 14,987 Vascular disorders **incl. 289 deaths**

**Total reactions** for the experimental mRNA vaccine **mRNA-1273 (CX-024414)** from **Moderna: 4,147 deaths** and **122,643 injuries** to 19/06/2021

- 2,239 Blood and lymphatic system disorders **incl. 29 deaths**
- 3,315 Cardiac disorders **incl. 446 deaths**
- 39 Congenital, familial and genetic disorders **incl. 3 deaths**
- 1,454 Ear and labyrinth disorders

- 82 Endocrine disorders **incl. 1 death**
- 1,883 Eye disorders **incl. 7 deaths**
- 10,655 Gastrointestinal disorders **incl. 142 deaths**
- 33,936 General disorders and administration site conditions **incl. 1,759 deaths**
- 209 Hepatobiliary disorders **incl. 11 deaths**
- 1,117 Immune system disorders **incl. 5 deaths**
- 3,835 Infections and infestations **incl. 234 deaths**
- 2,480 Injury, poisoning and procedural complications **incl. 77 deaths**
- 2,670 Investigations **incl. 89 deaths**
- 1,297 Metabolism and nutrition disorders **incl. 85 deaths**
- 15,131 Musculoskeletal and connective tissue disorders **incl. 77 deaths**
- 128 Neoplasms benign, malignant and unspecified (incl. cysts and polyps) **incl. 15 deaths**
- 21,684 Nervous system disorders **incl. 424 deaths**
- 255 Pregnancy, puerperium and perinatal conditions **incl. 2 death**
- 20 Product issues
- 2,437 Psychiatric disorders **incl. 69 deaths**
- 807 Renal and urinary disorders **incl. 52 deaths**
- 459 Reproductive system and breast disorders **incl. 1 death**
- 5,640 Respiratory, thoracic and mediastinal disorders **incl. 399 deaths**
- 6,538 Skin and subcutaneous tissue disorders **incl. 28 deaths**
- 504 Social circumstances **incl. 13 deaths**
- 397 Surgical and medical procedures **incl. 38 deaths**
- 3,432 Vascular disorders **incl. 141 deaths**

**Total reactions for the experimental vaccine AZD1222/VAXZEVRIA (CHADOX1 NCOV-19) from Oxford/ AstraZeneca: 3,364 deaths and 793,036 injuries to 19/06/2021**

- 9,136 Blood and lymphatic system disorders **incl. 132 deaths**
- 12,135 Cardiac disorders **incl. 396 deaths**
- 95 Congenital, familial and genetic disorders **incl. 2 deaths**
- 8,797 Ear and labyrinth disorders
- 309 Endocrine disorders **incl. 2 deaths**
- 13,459 Eye disorders **incl. 12 deaths**
- 81,806 Gastrointestinal disorders **incl. 161 deaths**
- 212,663 General disorders and administration site conditions **incl. 891 deaths**
- 525 Hepatobiliary disorders **incl. 25 deaths**
- 3,085 Immune system disorders **incl. 11 deaths**
- 17,791 Infections and infestations **incl. 217 deaths**
- 7,854 Injury, poisoning and procedural complications **incl. 77 deaths**
- 16,731 Investigations **incl. 79 deaths**
- 9,765 Metabolism and nutrition disorders **incl. 50 deaths**
- 123,637 Musculoskeletal and connective tissue disorders **incl. 45 deaths**
- 332 Neoplasms benign, malignant and unspecified (incl. cysts and polyps) **incl. 8 deaths**
- 169,286 Nervous system disorders **incl. 532 deaths**
- 223 Pregnancy, puerperium and perinatal conditions **incl. 4 deaths**
- 103 Product issues

- 14,931 Psychiatric disorders **incl. 27 deaths**
- 2,809 Renal and urinary disorders **incl. 29 deaths**
- 5,967 Reproductive system and breast disorders
- 26,631 Respiratory, thoracic and mediastinal disorders **incl. 387 deaths**
- 36,457 Skin and subcutaneous tissue disorders **incl. 22 deaths**
- 772 Social circumstances **incl. 4 deaths**
- 671 Surgical and medical procedures **incl. 16 deaths**
- 17,066 Vascular disorders **incl. 235 deaths**

**Total reactions for the experimental COVID-19 vaccine JANSSEN (AD26.COVS.2.S) from Johnson & Johnson: 541 deaths and 33, 331 injuries to 19/06/2021**

- 306 Blood and lymphatic system disorders **incl. 16 deaths**
- 496 Cardiac disorders **incl. 56 deaths**
- 14 Congenital, familial and genetic disorders
- 177 Ear and labyrinth disorders
- 8 Endocrine disorders **incl. 1 death**
- 383 Eye disorders **incl. 3 deaths**
- 3,086 Gastrointestinal disorders **incl. 23 deaths**
- 8,761 General disorders and administration site conditions **incl. 137 deaths**
- 52 Hepatobiliary disorders **incl. 4 deaths**
- 85 Immune system disorders
- 392 Infections and infestations **incl. 13 deaths**
- 320 Injury, poisoning and procedural complications **incl. 8 deaths**
- 2,003 Investigations **incl. 37 deaths**
- 184 Metabolism and nutrition disorders **incl. 10 deaths**
- 5,718 Musculoskeletal and connective tissue disorders **incl. 17 deaths**
- 16 Neoplasms benign, malignant and unspecified (incl. cysts and polyps)
- 7,093 Nervous system disorders **incl. 68 deaths**
- 9 Pregnancy, puerperium and perinatal conditions **incl. 1 death**
- 9 Product issues
- 355 Psychiatric disorders **incl. 5 deaths**
- 119 Renal and urinary disorders **incl. 8 deaths**
- 114 Reproductive system and breast disorders
- 1,130 Respiratory, thoracic and mediastinal disorders **incl. 43 deaths**
- 804 Skin and subcutaneous tissue disorders **incl. 2 deaths**
- 72 Social circumstances **incl. 3 deaths**
- 336 Surgical and medical procedures **incl. 26 deaths**
- 1,289 Vascular disorders **incl. 60 deaths**

Last Update: Jun 19 2021	Reported Cases	Fatalities	% fatalities to cases	All Multiple Symptoms	Serious injuries	% serious to ALL
<b>Astrazeneca</b>	292 283	3 364	1,15%	793 036	438 722	55,32%
<b>Pfizer-BioNTech</b>	238 435	7 420	3,11%	560 256	235 109	41,96%
<b>Moderna</b>	49 323	4 147	8,41%	122 643	68 569	55,91%
<b>Janssen</b>	11 276	541	4,80%	33 331	11 257	33,77%
<b>Total:</b>	<b>591 317</b>	<b>15 472</b>	2,62%	<b>1 509 266</b>	<b>753 657</b>	49,94%

\*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg\_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

## Notes

[1] These totals are estimates based on reports submitted to [EudraVigilance](#). Totals may be much higher based on percentage of adverse reactions that are reported. Some of these reports may also be reported to the individual country's adverse reaction databases, such as the U.S. VAERS database and the UK Yellow Card system. The fatalities are grouped by symptoms, and some fatalities may have resulted from multiple symptoms.

*Featured image is from Ali Raza from PxHere.*

The original source of this article is [Health Impact News](#)  
Copyright © [Brian Shilhavy](#), [Health Impact News](#), 2021

---

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Brian Shilhavy](#)

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)  
[www.globalresearch.ca](http://www.globalresearch.ca) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)